Eli Lilly (LLY) shares clocked seven straight sessions of losses on Friday, as the stock was 0.5% lower at $1,009.15.
The pharmaceutical giant lost 8% in the preceding six sessions. Overall, the stock has climbed 32% so far this year, compared to the 16% rise in the broader S&P 500 Index (SP500).
LLY is up 9% over the past one month.
Most recently, Eli Lilly announced that the drugmaker is cutting prices for starting doses of Zepbound single-dose vials on its LillyDirect direct-to-consumer platform.
Looking at Seeking Alpha’s Quant Rating, LLY has a Hold rating with a score of 3.4 out of 5. The company received A+ in the prospect of profitability, while it received D- in the valuation factor.
Seeking Alpha analysts are positive and see the stock as a Buy.
Turing to the Wall Street, 21 analysts have given the stock a Buy or above rating. Eight gave the stock hold recommendation, while one gave Sell rating to LLY.
“LLY’s future growth is fueled by pipeline drugs, expanded manufacturing, and strategic collaborations but faces high debt and premium valuation risks,” pointed out a recent Seeking Alpha analysis.